US20040152963A1 - Apparatus for measuring blood glucose concentrations - Google Patents

Apparatus for measuring blood glucose concentrations Download PDF

Info

Publication number
US20040152963A1
US20040152963A1 US10/474,862 US47486204A US2004152963A1 US 20040152963 A1 US20040152963 A1 US 20040152963A1 US 47486204 A US47486204 A US 47486204A US 2004152963 A1 US2004152963 A1 US 2004152963A1
Authority
US
United States
Prior art keywords
fluorescence
ocular
glucose
blood glucose
optical path
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/474,862
Inventor
Wayne March
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyesense AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20040152963A1 publication Critical patent/US20040152963A1/en
Priority to US11/377,609 priority Critical patent/US7653424B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARCH, WAYNE FRONT
Assigned to EYESENSE AG reassignment EYESENSE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS AG
Priority to US12/692,625 priority patent/US20100185066A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement

Definitions

  • the present invention provides an apparatus for measuring ocular and/or blood glucose levels, in particular by measuring fluorescence intensities simultaneously at two wavelengths.
  • the apparatus is useful for accurately monitoring ocular and/or blood glucose levels.
  • WO-A-01/13783 discloses an ocular sensor for glucose that can be used to monitor blood glucose levels by determining glucose levels in an ocular fluid, such as tears, aqueous humor, or interstitial fluid.
  • the ocular sensor disclosed by WO-A-01/13783 is an ophthalmic lens comprising a glucose receptor labeled with a first fluorescent label and a glucose competitor labeled with a second fluorescent label. The two fluorescent labels are selected in a way that while the competitor is bound to the receptor, the fluorescence of the second fluorescent label is quenched via a fluorescence resonance energy transfer.
  • the amount of the fluorescently labeled competitor that is displayed from the receptor by glucose is measured and provides a means of determining glucose concentration in an ocular fluid. This measurement can, in turn, be manipulated to provide a measurement of blood glucose level.
  • One of useful features of the method of WO-A-01/13783 for determining blood glucose levels using an ocular glucose sensor is that one of the two fluorescent labels could serve as an internal standard in the determination of glucose concentration in an ocular fluid and thereby could enhance the accuracy of determination of glucose concentration in an ocular fluid.
  • the existence of an internal standard also could minimize the effects of positioning of the apparatus relative to the eye of a user on the reproducibility and accuracy of tests of blood glucose.
  • the present invention in one aspect, provides an apparatus for measuring ocular and/or blood glucose levels.
  • the apparatus of the invention comprises: (a) an irradiating means for irradiating light onto the eye of a user from outside the cornea of the eye to excite an ocular glucose sensor, wherein said ocular glucose sensor is in contact with an ocular fluid and can emit a total fluorescence having a first and a second wavelength bands upon irradiation with said irradiating means; (b) an optical path splitting means for splitting said total fluorescence having both bands into a first fluorescence having said first wavelength band and second fluorescence having said second wavelength band, wherein said first fluorescence travels along a first optical path and said second fluorescence travels along a second optical path; (c) a first detecting means located in the first optical path for detecting the intensity of the first fluorescence at a first wavelength; (d) a second detecting means located in the second optical path for detecting the intensity of the second fluorescence
  • ocular glucose concentration refers to a glucose concentration in an ocular fluid.
  • blood glucose concentration refers to a glucose concentration in the blood stream of a person.
  • An ocular sensor is an ophthalmic lens comprising a glucose receptor labeled with a first fluorescent label and a glucose competitor labeled with a second fluorescent label.
  • the two fluorescent labels are selected in a way that while the competitor is bound to the receptor, the fluorescence of one of two fluorescent labels is quenched via a fluorescence resonance energy transfer by the other fluorescent label.
  • the amount of the fluorescently labeled competitor that is displayed from the receptor by glucose is measured and provides a means of determining glucose concentration in an ocular fluid.
  • Fluorescent labels such as fluorescein, indocyanine green, malachite green, and rhodamine, which are quenched when the competitor moiety is bound but are unquenched when the competitor moiety is not bound, are preferred for use as quenchable fluorescent label in ocular glucose sensor.
  • the sensitivity of the ocular glucose sensor can be controlled by altering the concentration of the quenchable fluorescent label. Increasing the concentration of the quenchable fluorescent label in the ocular glucose sensor increases the range of fluorescence intensity and thereby increases the sensivity of resulting measurements.
  • the glucose receptor moiety comprises a binding site for glucose.
  • the binding site also binds a moiety that competes with glucose for binding and is therefore referred to herein as a “glucose/competitor moiety binding site”. Binding of both the competitor moiety and glucose to the glucose/competitor moiety binding site is reversible.
  • the receptor moiety can be antibodies, boronic acid, a genetically engineered bacterial fluoriprotein, or glucose oxidase, or preferably concanavalin A (Mansouri & Schultz, Bio/Tech 2:385 (1984)).
  • competitor moieties can be fluorescein dextran (which competes with glucose for binding to concanavalin A).
  • An ophthalmic lens can be removable lens, such as a contact lens, or a permanently implanted lens, such as an intraocular lens, a subconjunctival lens, or an intracorneal lens.
  • Permanentiy implanted lenses are particularly well-suited for use in individuals who have compromised ocular function (e.g., cataracts) and also diabetic disease.
  • Ophthalmic lenses can be corrective lenses or can be constructed so that they do not affect visual acuity.
  • Contact lenses optionally can comprise a tint and are preferably disposable, which reduces the risk of infection for the user.
  • the term “ophthalmic lens” may also refer to a shunt or implant that may rest in the cul de sac of the eye.
  • Ophthalmic lenses according to embodiments of the invention can be worn chronically to provide repeated measurements or can be worn for a single measurement. Both qualitative and quantitative measurements can be performed.
  • Intracorneal lenses are taught, inter alia, in U.S. Pat. Nos. 6,090,141, 5,984,961, 5,123,921, and 4,799,931.
  • the receptor moiety can be covalently bound to the ophthalmic lens material.
  • the ophthalmic lens comprises a polymer meshwork containing pores. The pores are of a size which permit the competitor moiety to bind reversibly to the glucose/competitor moiety binding site, but which prevent the receptor moiety and the competitor moiety from diffusing out of the ophthalmic lens.
  • Suitable polymers for this purpose are known in the art and include hydrogels, such as stable polymers of polyethylene glycol hydrogel (PEGH), and modified polyvinylalcohol, such as neflilcon A.
  • the ophthalmic lens comprises a receptor moiety layer, a polyelectrolyte layer, and a competitor moiety layer.
  • the polyelectrolyte layer includes one or more polyelectrolytes, which are generally high molecular weight polymers with multiple ionic or ionizable functional groups. At least one polyelectrolyte in the polyelectrolyte layer has a charge opposite to the overall charge of the receptor moiety and competitor moiety layers.
  • Suitable polyelectrolytes include positively charged PDDA (polydiallyldimethyl-ammonium chloride) and negatively charged PAA (polyacrylic acid). Assembly of the layers is based upon sequential adsorption of opposiely charged polyions.
  • the sensor and spacing polyelectrolytes are deposited as uniform thin films (1-10 nm) in 10-15 deposition cycles onto the porous polyvinyl alcohol or hydrogel matrix, resulting in only a 100-500 nm thick coating for the sensing film, which is highly blocompatible.
  • a typical sequence for construction of an ophthalmic lens suitable for glucose detection involves a deposition cycle of ultrathin (1-10 nm) films of PDDA, PAA, PDDA, concanavalin A, PDDA, PAA, PDDA, fluorescein dextran, PDDA, PAA, PDDA, PAA, concanavalin A, PAA, fluorescein dextran, PAA, etc.
  • Technology for constructing ophthalmic lenses comprising such layers is taught, for example, in WO-A-99/35520.
  • a calibration table or calibration curve as used herein means a table or curve containing in correlated form fluorescence intensity ratios and their corresponding actual glucose concentrations.
  • a calibration table or calibration curve can be obtained once a day or just before testing of blood glucose levels by using at least three standard solutions with known glucose concentrations over a glucose concentration range from 0 to 500 mg/L. The obtained calibration table or curve is preferably stored in the apparatus which is used subsequently to determine blood glucose concentration.
  • Standard solutions can be provided to a user in calibration kits. They are stored in containers, preferably a rectangular having a plurality of separate compartments. The kits can also include calibration instruction.
  • FIG. 1 is a schematic view showing the construction of an apparatus for measuring ocular glucose concentrations according one embodiment of the invention.
  • the apparatus includes convex lenses 2 , 4 and 5 , polarizer 3 , mirrors 6 , 7 , 19 , and 20 , apertures 8 , 13 and 16 , light emitting diode 10 serving as irradiating means, a dichroic beamspliter 11 , two photomultiplier tubes (PMT) 14 and 17 serving as detecting means, filter 9 , a pupil alignment viewer 21 , a power supplier (not shown), a processing circuit (not shown) serving as both calculating and arithmetic means for determining ocular/blood glucose concentration, and a light-emitting display panel serving as means for displays blood glucose concentrations.
  • PMT photomultiplier tubes
  • the dichrolc beamsplitter 11 is used to split the fluorescence from the eye 1 into a first fluorescence having a first wavelength band and a second fluorescence having a second wavelength band, so that the PMTs 14 and 17 can simultaneously measure the intensities of the first and second fluorescences at two different wavelengths.
  • the subject By observing on the pupil alignment viewer 21 , with his or her own eye 1 , the subject is capable of verifying that the excitation light emitted by the LED 10 is focused on the pupil of the eye via the convex lenses 2 and 18 , mirrors 19 and 20 , and polarizer 3 .
  • the processing circuit obtains predetermined calibration table or curve of fluorescence intensity ratios and their corresponding actual glucose concentration and predetermined correlation between the blood glucose concentration and ocular glucose concentration.
  • the measured blood glucose value is displayed on the light-emitting display panel. Further, the measured blood glucose concentration value may be transmitted to another piece of equipment via wire or cable, or wirelessly, such as via radio frequency or infrared transmission.
  • a telemetry signal can be transmitted to an infusion pump, which can provide insulin to maintain suitable levels of glucose in the body.
  • the telemetry signal may be analog or digital.
  • Infusion pumps are well known in the art for delivering a selected medication to a patient incduding humans and other animals in accordance with an administration schedule which can be preselected or, in some instances, preprogrammed.
  • Pumps for use in this invention can be worn externally or can be directly implanted into the body of a mammal, including a human, to deliver a specific insulin to the mammal in controlled doses over an extended period of time.
  • Such pumps are well known and are described, for example, in U.S. Pat. Nos. 5,957,890, 4,923,375, 4,573,994, and 3,731,681.
  • the measured blood glucose concentration value may be transmitted to another piece of equipment via wire or cable, or wirelessly, such as via radio frequency or infrared transmission.
  • a telemetry signal can be transmitted to an infusion pump, which can provide insulin to maintain suitable levels of glucose in the body.
  • the telemetry signal may be analog or digital.
  • the apparatus of the invention can be a free-standing device, a table-top device, or a handheld device.
  • the detector can be a miniaturized device and may be worn or carried as a personal accessory, for example, mounted in the frame of a pair of eye glasses.
  • PEGH polyethylene glycol hydrogel
  • Shearwater Polymers, Inc. is used to construct an intraocular glucose sensor.
  • PEGH is immobilized in an intraocular lens (Alcon Laboratories, 6 mm circumference, 1 mm thickness).
  • Chemically immobilized pendant tetramethylrhodamine isothiocyanate concanavalin A (TRITC-ConA, Sigma) is incorporated into the PEGH as the receptor moiety and fluorescein isothiocyanate dextran (FITC-dextran, Sigma) is incorporated as the competitor moiety by polymerization under UV light, as described by Ballerstadt & Schultz, Anal. Chim.
  • the intraocular lens glucose sensor described in Example 1 is implanted into the anterior chamber of the eye of a living New Zealand rabbit with a blood glucose concentration of 112 mg %.
  • the implant is visible as a bright spot of green fluorescence (518 nm) within the eye.
  • Careful examination with a bio-microscope slit lamp shows no sign of toxicity, rejection, or any reaction 6 months after implantation.
  • An apparatus is constructed according to the scheme shown in FIG. 1 to measure fluorescence from both fluorescin (517 nm) and rhodamine (570 nm).
  • the apparatus has two excitation sources, one for fluorescein and one for rhodamine.
  • Two photomultiplier tubes are employed to maximize the sensing of the signal at two wavelengths (517 nm and 570 nm). Detection of fluorescence from the encapsulated intraocular glucose sensor implanted in a rabbit eye is tested.
  • fluorescence changes in response to glucose addition (0-500 mg/dl) to the sensor (fluorescin-dextran bound to rhodamine-concanavalin) in solution are monitored by the apparatus and compared to data obtained using a conventional laboratory scanning fluorophotometer (SpexFluorolog).
  • the ocular implant in the rabbit emits green fluorescence at 517 nm when excited with blue light at 488 nm.
  • emitted fluorescence intensity at 517 nm increases linearly with increasing glucose concentrations below 22 nM (400 mg/L), whether the fluorescence is recorded by the apparatus or the laboratory fluorophotmeters.
  • fluorescence at 517 nm emitted from solutions increases by more than 30% compared to glucose-free controls.

Abstract

An apparatus for measuring ocular and/or blood glucose levels comprises (a) an irradiating means (10) for irradiating light onto the eye (1) of a user from outside the cornea of the eye to excite an ocular glucose sensor in contact with an ocular fluid, said sensor being able to emit a total fluorescence having first and a second wavelength bands; (b) an optical path splitting means (11) for splitting said total fluorescence into a first fluorescence and a second fluorescence, said first fluorescence and said second fluorescence travelling along first and second optical paths; (c) a first detecting means (14) located in the first optical path; (d) a second detecting means (17) located in the second optical path; (e) a calculating means for calculating the intensity ratio or the first fluorecence to the second fluorescence and for determining an ocular glucose concentration in the ocular fluid; and (f) an arithmetic means for converting the ocular glucose concentration into a blood glucose concentration.

Description

  • The present invention provides an apparatus for measuring ocular and/or blood glucose levels, in particular by measuring fluorescence intensities simultaneously at two wavelengths. The apparatus is useful for accurately monitoring ocular and/or blood glucose levels. [0001]
  • One important aspect in the treatment of diabetes is the tight control of blood glucose levels, which requires frequent monitoring of blood glucose levels of patients so as to manage food intake and the dosage and timing of insulin injection. Currently, millions of diabetics are forced to draw blood daily to determine their blood sugar levels. To alleviate the constant discomfort and inconvenience of these individuals, substantial effort has been expanded in the search for a non-invasive or minimally invasive technology to accurately determine blood glucose levels. [0002]
  • Various non-invasive or minimally invasive technologies to measure blood glucose levels have been described. For example, WO-A-01/13783 discloses an ocular sensor for glucose that can be used to monitor blood glucose levels by determining glucose levels in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The ocular sensor disclosed by WO-A-01/13783 is an ophthalmic lens comprising a glucose receptor labeled with a first fluorescent label and a glucose competitor labeled with a second fluorescent label. The two fluorescent labels are selected in a way that while the competitor is bound to the receptor, the fluorescence of the second fluorescent label is quenched via a fluorescence resonance energy transfer. By monitoring change of the fluorescence intensity at a wavelength around the peak of the fluorescence of the second fluorescent label, the amount of the fluorescently labeled competitor that is displayed from the receptor by glucose is measured and provides a means of determining glucose concentration in an ocular fluid. This measurement can, in turn, be manipulated to provide a measurement of blood glucose level. [0003]
  • One of useful features of the method of WO-A-01/13783 for determining blood glucose levels using an ocular glucose sensor is that one of the two fluorescent labels could serve as an internal standard in the determination of glucose concentration in an ocular fluid and thereby could enhance the accuracy of determination of glucose concentration in an ocular fluid. The existence of an internal standard also could minimize the effects of positioning of the apparatus relative to the eye of a user on the reproducibility and accuracy of tests of blood glucose. [0004]
  • However, such feature can not be fully utilized, because currently available fluorophotometers are not capable of measuring simultaneously and accurately two fluorescence intensifies at two different wavelengths. Accordingly, there is need for developing an affordable apparatus for accurately determining ocular glucose levels by measuring two fluorescence intensities at two different wavelengths and in turn for determining blood glucose levels. [0005]
  • Furthermore, like commercial in vitro (invasive) measurement instruments, i.e., those which require a drop of blood to measure blood glucose content, the accuracy and stability of an apparatus for measuring ocular glucose levels is needed to be verified periodically. Considering that most diabetic patients are not skilled in the art of fluorophotometer calibration, there is also need for developing methods and kits for calibrating an apparatus for measuring ocular glucose levels. [0006]
  • The present invention, in one aspect, provides an apparatus for measuring ocular and/or blood glucose levels. The apparatus of the invention comprises: (a) an irradiating means for irradiating light onto the eye of a user from outside the cornea of the eye to excite an ocular glucose sensor, wherein said ocular glucose sensor is in contact with an ocular fluid and can emit a total fluorescence having a first and a second wavelength bands upon irradiation with said irradiating means; (b) an optical path splitting means for splitting said total fluorescence having both bands into a first fluorescence having said first wavelength band and second fluorescence having said second wavelength band, wherein said first fluorescence travels along a first optical path and said second fluorescence travels along a second optical path; (c) a first detecting means located in the first optical path for detecting the intensity of the first fluorescence at a first wavelength; (d) a second detecting means located in the second optical path for detecting the intensity of the second fluorescence at a second wavelength; (e) a calculating means for calculating the intensity ratio of the first fluorescence to the second fluorescence and for determining based on the calculated intensity ratio an ocular glucose concentration in the ocular fluid of the user according to a predetermined calibration table or calibration curve; and (f) an arithmetic means for converting the ocular glucose concentration determined by the calculating means into a blood glucose concentration by referring to a predetermined correlation between blood glucose concentrations and ocular glucose concentrations. The present invention, in a further aspect, provides kits for calibrating an apparatus for measuring ocular glucose concentrations. [0007]
  • The term “ocular glucose concentration” as used herein refers to a glucose concentration in an ocular fluid. [0008]
  • The term “blood glucose concentration” as used herein refers to a glucose concentration in the blood stream of a person. [0009]
  • An ocular sensor is an ophthalmic lens comprising a glucose receptor labeled with a first fluorescent label and a glucose competitor labeled with a second fluorescent label. The two fluorescent labels are selected in a way that while the competitor is bound to the receptor, the fluorescence of one of two fluorescent labels is quenched via a fluorescence resonance energy transfer by the other fluorescent label. By monitoring change of the fluorescence intensity at a wavelength around the peak of the fluorescence of the quenchable fluorescent label, the amount of the fluorescently labeled competitor that is displayed from the receptor by glucose is measured and provides a means of determining glucose concentration in an ocular fluid. [0010]
  • Fluorescent labels, such as fluorescein, indocyanine green, malachite green, and rhodamine, which are quenched when the competitor moiety is bound but are unquenched when the competitor moiety is not bound, are preferred for use as quenchable fluorescent label in ocular glucose sensor. [0011]
  • The sensitivity of the ocular glucose sensor can be controlled by altering the concentration of the quenchable fluorescent label. Increasing the concentration of the quenchable fluorescent label in the ocular glucose sensor increases the range of fluorescence intensity and thereby increases the sensivity of resulting measurements. [0012]
  • The glucose receptor moiety comprises a binding site for glucose. The binding site also binds a moiety that competes with glucose for binding and is therefore referred to herein as a “glucose/competitor moiety binding site”. Binding of both the competitor moiety and glucose to the glucose/competitor moiety binding site is reversible. The receptor moiety can be antibodies, boronic acid, a genetically engineered bacterial fluoriprotein, or glucose oxidase, or preferably concanavalin A (Mansouri & Schultz, Bio/Tech 2:385 (1984)). [0013]
  • It is well known to a person skiled in the art to select a competitor moiety which will compete with glucose for binding to a glucose/competitor moiety binding site. For example, competitor moieties can be fluorescein dextran (which competes with glucose for binding to concanavalin A). [0014]
  • An ophthalmic lens can be removable lens, such as a contact lens, or a permanently implanted lens, such as an intraocular lens, a subconjunctival lens, or an intracorneal lens. Permanentiy implanted lenses are particularly well-suited for use in individuals who have compromised ocular function (e.g., cataracts) and also diabetic disease. [0015]
  • Ophthalmic lenses can be corrective lenses or can be constructed so that they do not affect visual acuity. Contact lenses optionally can comprise a tint and are preferably disposable, which reduces the risk of infection for the user. As used herein, the term “ophthalmic lens” may also refer to a shunt or implant that may rest in the cul de sac of the eye. [0016]
  • Ophthalmic lenses according to embodiments of the invention can be worn chronically to provide repeated measurements or can be worn for a single measurement. Both qualitative and quantitative measurements can be performed. [0017]
  • Construction of various types of ophthalmic lenses is well known in the art. Construction of contact lenses is taught, for example, in U.S. Pat. Nos. 5,965,631, 5,894,002, 5,849,811, 5,807,944, 5,776,381, 5,426,158, 4,099,859, 4,229,273, 4,168,112, 4,217,038, 4,409,258, 4,388,164, 4,332,922, 4,143,949, 4,311,573, 4,589,964, and 3,925,178. [0018]
  • Construction of intraocular lens implants is taught, inter alia, in U.S. Pat. Nos. 6,051,025, 5,868,697, 5,762,836, 5,609,640, 5,071,432, 5,041,133, and 5,007,928. Subconjunctival lenses are taught, for example, in U.S. Pat. Nos. 5,476,511, 5,400,114, and 5,127,901. [0019]
  • Intracorneal lenses are taught, inter alia, in U.S. Pat. Nos. 6,090,141, 5,984,961, 5,123,921, and 4,799,931. [0020]
  • A variety of options are available for providing the receptor and competitor moieties in an ophthalmic lens. In one embodiment, the receptor moiety can be covalently bound to the ophthalmic lens material. In another embodiment, the ophthalmic lens comprises a polymer meshwork containing pores. The pores are of a size which permit the competitor moiety to bind reversibly to the glucose/competitor moiety binding site, but which prevent the receptor moiety and the competitor moiety from diffusing out of the ophthalmic lens. Suitable polymers for this purpose are known in the art and include hydrogels, such as stable polymers of polyethylene glycol hydrogel (PEGH), and modified polyvinylalcohol, such as neflilcon A. [0021]
  • In another embodiment, the ophthalmic lens comprises a receptor moiety layer, a polyelectrolyte layer, and a competitor moiety layer. The polyelectrolyte layer includes one or more polyelectrolytes, which are generally high molecular weight polymers with multiple ionic or ionizable functional groups. At least one polyelectrolyte in the polyelectrolyte layer has a charge opposite to the overall charge of the receptor moiety and competitor moiety layers. Suitable polyelectrolytes include positively charged PDDA (polydiallyldimethyl-ammonium chloride) and negatively charged PAA (polyacrylic acid). Assembly of the layers is based upon sequential adsorption of opposiely charged polyions. The sensor and spacing polyelectrolytes are deposited as uniform thin films (1-10 nm) in 10-15 deposition cycles onto the porous polyvinyl alcohol or hydrogel matrix, resulting in only a 100-500 nm thick coating for the sensing film, which is highly blocompatible. A typical sequence for construction of an ophthalmic lens suitable for glucose detection involves a deposition cycle of ultrathin (1-10 nm) films of PDDA, PAA, PDDA, concanavalin A, PDDA, PAA, PDDA, fluorescein dextran, PDDA, PAA, PDDA, PAA, concanavalin A, PAA, fluorescein dextran, PAA, etc. Technology for constructing ophthalmic lenses comprising such layers is taught, for example, in WO-A-99/35520. [0022]
  • A calibration table or calibration curve as used herein means a table or curve containing in correlated form fluorescence intensity ratios and their corresponding actual glucose concentrations. A calibration table or calibration curve can be obtained once a day or just before testing of blood glucose levels by using at least three standard solutions with known glucose concentrations over a glucose concentration range from 0 to 500 mg/L. The obtained calibration table or curve is preferably stored in the apparatus which is used subsequently to determine blood glucose concentration. [0023]
  • Standard solutions can be provided to a user in calibration kits. They are stored in containers, preferably a rectangular having a plurality of separate compartments. The kits can also include calibration instruction. [0024]
  • The correlation between blood glucose concentration and ocular glucose concentration can be determined by methods well known in the art. See, for example, March et al., Diabetes Care 5,259-65, 1982; Süllmann, in Handbuch der Physlologischen Chemie, Vol. II/a, p. 867 ff., Springer, Berlin, 1956; Graymore, in The Eye, Vol. I, p. 348, Davson, ed., Academic Press, NY, 1962; De Berardinis et al., Exp. Eye Res. 4,179,1965; Pohjola, Acta Ophthalmologica Suppl. 88, 1966; Reim et al., Ophthalmologica 154, 39-50, 1967; Kinsey & Reddy, in Prince, ed., The Rabbit and Eye Research, C. C. Thomas. Springfield, Ill., 1964, p. 218. It is preferably that such correlation between blood glucose concentration and ocular glucose concentration can be stored in the apparatus of the present invention so that the measurement of ocular glucose concentration can be converted into a value of blood glucose concentration.[0025]
  • FIG. 1 is a schematic view showing the construction of an apparatus for measuring ocular glucose concentrations according one embodiment of the invention. The apparatus includes [0026] convex lenses 2, 4 and 5, polarizer 3, mirrors 6, 7, 19, and 20, apertures 8, 13 and 16, light emitting diode 10 serving as irradiating means, a dichroic beamspliter 11, two photomultiplier tubes (PMT) 14 and 17 serving as detecting means, filter 9, a pupil alignment viewer 21, a power supplier (not shown), a processing circuit (not shown) serving as both calculating and arithmetic means for determining ocular/blood glucose concentration, and a light-emitting display panel serving as means for displays blood glucose concentrations. The dichrolc beamsplitter 11 is used to split the fluorescence from the eye 1 into a first fluorescence having a first wavelength band and a second fluorescence having a second wavelength band, so that the PMTs 14 and 17 can simultaneously measure the intensities of the first and second fluorescences at two different wavelengths. By observing on the pupil alignment viewer 21, with his or her own eye 1, the subject is capable of verifying that the excitation light emitted by the LED 10 is focused on the pupil of the eye via the convex lenses 2 and 18, mirrors 19 and 20, and polarizer 3.
  • The processing circuit obtains predetermined calibration table or curve of fluorescence intensity ratios and their corresponding actual glucose concentration and predetermined correlation between the blood glucose concentration and ocular glucose concentration. The measured blood glucose value is displayed on the light-emitting display panel. Further, the measured blood glucose concentration value may be transmitted to another piece of equipment via wire or cable, or wirelessly, such as via radio frequency or infrared transmission. A telemetry signal can be transmitted to an infusion pump, which can provide insulin to maintain suitable levels of glucose in the body. The telemetry signal may be analog or digital. [0027]
  • Infusion pumps are well known in the art for delivering a selected medication to a patient incduding humans and other animals in accordance with an administration schedule which can be preselected or, in some instances, preprogrammed. Pumps for use in this invention can be worn externally or can be directly implanted into the body of a mammal, including a human, to deliver a specific insulin to the mammal in controlled doses over an extended period of time. Such pumps are well known and are described, for example, in U.S. Pat. Nos. 5,957,890, 4,923,375, 4,573,994, and 3,731,681. Further, the measured blood glucose concentration value may be transmitted to another piece of equipment via wire or cable, or wirelessly, such as via radio frequency or infrared transmission. A telemetry signal can be transmitted to an infusion pump, which can provide insulin to maintain suitable levels of glucose in the body. The telemetry signal may be analog or digital. [0028]
  • The apparatus of the invention can be a free-standing device, a table-top device, or a handheld device. For convenience, the detector can be a miniaturized device and may be worn or carried as a personal accessory, for example, mounted in the frame of a pair of eye glasses. [0029]
  • In order to better enable the reader to understand specific embodiments and the advantages thereof, reference to the following non-limiting examples is suggested. [0030]
  • EXAMPLE 1
  • Construction of an Intraocular Glucose Sensor [0031]
  • A structurally stable polymer of polyethylene glycol hydrogel (PEGH, Shearwater Polymers, Inc.) is used to construct an intraocular glucose sensor. PEGH is immobilized in an intraocular lens (Alcon Laboratories, 6 mm circumference, 1 mm thickness). Chemically immobilized pendant tetramethylrhodamine isothiocyanate concanavalin A (TRITC-ConA, Sigma) is incorporated into the PEGH as the receptor moiety and fluorescein isothiocyanate dextran (FITC-dextran, Sigma) is incorporated as the competitor moiety by polymerization under UV light, as described by Ballerstadt & Schultz, Anal. Chim. Acta 345, 203-12, 1997, and Russell & Pishko, Anal. Chem. 71, 3126-32, 1999. While the FITC-dextran is bound to the TRITC-ConA, the FITC fluorescence is quenched via a fluorescence resonance energy transfer. Increased glucose concentration frees the FITC-dextran and results in fluorescence which is proportional to glucose concentration. [0032]
  • EXAMPLE 2
  • Implantation of an Intraocular Glucose Sensor In Vivo [0033]
  • The intraocular lens glucose sensor described in Example 1 is implanted into the anterior chamber of the eye of a living New Zealand rabbit with a blood glucose concentration of 112 mg %. The implant is visible as a bright spot of green fluorescence (518 nm) within the eye. Careful examination with a bio-microscope slit lamp shows no sign of toxicity, rejection, or any reaction 6 months after implantation. [0034]
  • EXAMPLE 3
  • An apparatus is constructed according to the scheme shown in FIG. 1 to measure fluorescence from both fluorescin (517 nm) and rhodamine (570 nm). The apparatus has two excitation sources, one for fluorescein and one for rhodamine. Two photomultiplier tubes are employed to maximize the sensing of the signal at two wavelengths (517 nm and 570 nm). Detection of fluorescence from the encapsulated intraocular glucose sensor implanted in a rabbit eye is tested. In addition, fluorescence changes in response to glucose addition (0-500 mg/dl) to the sensor (fluorescin-dextran bound to rhodamine-concanavalin) in solution are monitored by the apparatus and compared to data obtained using a conventional laboratory scanning fluorophotometer (SpexFluorolog). [0035]
  • The ocular implant in the rabbit emits green fluorescence at 517 nm when excited with blue light at 488 nm. With the glucose sensor in solution, emitted fluorescence intensity at 517 nm increases linearly with increasing glucose concentrations below 22 nM (400 mg/L), whether the fluorescence is recorded by the apparatus or the laboratory fluorophotmeters. After addition of 11 nM (200 mg/L) glucose, fluorescence at 517 nm emitted from solutions increases by more than 30% compared to glucose-free controls. [0036]

Claims (7)

1. An apparatus for measuring ocular and/or blood glucose levels, comprising:
(a) an irradiating means (10) for irradiating light onto the eye (1) of a user from outside the comea of the eye to excite an ocular glucose sensor, wherein said ocular glucose sensor is in contact with an ocular fluid and can emit a total fluorescence having a first and a second wavelength bands upon irradiation with said irradiating means (10);
(b) an optical path splitting means (11) for spritting said total fluorescence having both bands into a first fluorescence having said first wavelength band and second fluorescence having said second wavelength band, wherein said first fluorescence travels along a first optical path and said second fluorescence travels along a second optical path;
(c) a first detecting means (14) located in the first optical path for detecting the intensity of the first fluorescence at a first wavelength;
(d) a second detecting means (17) located in the second optical path for detecting the intensity of the second fluorescence at a second wavelength;
(e) a calculating means for calculating the intensity ratio of the first fluorescence to the second fluorescence and for determining based on the calculated intensity ratio an ocular glucose concentration in the ocular fluid of the user according to a predetermined calibration table or calibration curve; and
(f) an arithmetic means for converting the ocular glucose concentration determined by the calculating means into a blood glucose concentration by referring to a predetermined correlation between blood glucose concentrations and ocular glucose concentrations.
2. An apparatus according to claim 1, further comprising a displaying means for visually displaying the blood glucose concentration determined by the arithmetic means.
3. Anapparatus according to claim 1 or claim 2, further comprising a transmitting means for transmitting a signal to a pump, wherein said signal contains instructions for the pump to inject an amount of insulin into a tissue of the user.
4. An apparatus according to any one of the preceding claims, wherein said irradiating means (10) emits a light of third and fourth wavelengths which are different.
5. A kit for calibrating an apparatus according to any one of the preceding claims, comprising an apparatus according to any one of claims 1 to 4 and at least three solutions of known glucose concentrations which are different.
6. A kit according to claim 5, wherein said known glucose concentrations are evenly distributed over a concentration range from 0 to 500 mg/L.
7. A kit of claim 5 or claim 6, further comprising an instruction for calibrating the apparatus for measuring ocular glucose concentrations.
US10/474,862 2001-04-27 2002-04-26 Apparatus for measuring blood glucose concentrations Abandoned US20040152963A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/377,609 US7653424B2 (en) 2001-04-27 2006-03-16 Apparatus for measuring blood glucose concentrations
US12/692,625 US20100185066A1 (en) 2001-04-27 2010-01-24 Apparatus for measuring blood glucose concentrations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28705301P 2001-04-27 2001-04-27
PCT/EP2002/004647 WO2002087429A1 (en) 2001-04-27 2002-04-26 Apparatus for measuring blood glucose concentrations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/377,609 Continuation US7653424B2 (en) 2001-04-27 2006-03-16 Apparatus for measuring blood glucose concentrations

Publications (1)

Publication Number Publication Date
US20040152963A1 true US20040152963A1 (en) 2004-08-05

Family

ID=23101263

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/474,862 Abandoned US20040152963A1 (en) 2001-04-27 2002-04-26 Apparatus for measuring blood glucose concentrations
US11/377,609 Expired - Fee Related US7653424B2 (en) 2001-04-27 2006-03-16 Apparatus for measuring blood glucose concentrations
US12/692,625 Abandoned US20100185066A1 (en) 2001-04-27 2010-01-24 Apparatus for measuring blood glucose concentrations

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/377,609 Expired - Fee Related US7653424B2 (en) 2001-04-27 2006-03-16 Apparatus for measuring blood glucose concentrations
US12/692,625 Abandoned US20100185066A1 (en) 2001-04-27 2010-01-24 Apparatus for measuring blood glucose concentrations

Country Status (9)

Country Link
US (3) US20040152963A1 (en)
EP (1) EP1385423B1 (en)
JP (1) JP4152193B2 (en)
CA (1) CA2441787C (en)
DE (1) DE60223668T2 (en)
DK (1) DK1385423T3 (en)
ES (1) ES2295344T3 (en)
NO (1) NO20034777D0 (en)
WO (1) WO2002087429A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087843A1 (en) * 2002-08-26 2004-05-06 Rice Mark J. Non-invasive psychophysical measurement of glucose using photodynamics
US20040147820A1 (en) * 2001-09-13 2004-07-29 Fovioptics, Inc. Non-invasive measurement of blood analytes using photodynamics
US20050010091A1 (en) * 2003-06-10 2005-01-13 Woods Joe W. Non-invasive measurement of blood glucose using retinal imaging
US20070123761A1 (en) * 2003-12-12 2007-05-31 Daly Daniel J Extended focal region measuring apparatus and method
US20070256943A1 (en) * 2006-05-04 2007-11-08 Popovich Natasha D System and methods for automatically recognizing a control solution
US7651841B2 (en) * 2001-12-24 2010-01-26 Kimberly-Clark Worldwide, Inc. Polyelectrolytic internal calibration system of a flow-through assay
US7769419B2 (en) 2003-10-24 2010-08-03 Lein Applied Diagnostics Limited Ocular property measuring apparatus and method therefor
US20100210925A1 (en) * 2007-07-30 2010-08-19 Richard Holley Optical Apparatus for Measuring a Physiological Property of a Body Part and Method Therefore
US7781172B2 (en) 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US7943395B2 (en) 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US8137985B2 (en) 2001-12-24 2012-03-20 Kimberly-Clark Worldwide, Inc. Polyelectrolytic internal calibration system of a flow-through assay
US8696128B2 (en) 2007-07-30 2014-04-15 Lein Applied Diagnostics Optical measurement apparatus and method therefor
US9026188B2 (en) 2008-02-11 2015-05-05 Lein Applied Diagnostics Measurement apparatus and method therefor
EP2979662A1 (en) 2014-08-01 2016-02-03 Akkolens International B.V. Intraocular lens with electricity generator and additional functional systems
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964390B2 (en) * 2002-10-11 2011-06-21 Case Western Reserve University Sensor system
US20050038329A1 (en) * 2002-11-20 2005-02-17 Morris Carol Ann Methods and kits for assays of rapid screening of diabetes
DE602004007771T2 (en) 2003-02-14 2007-12-06 Eyesense Ag DEVICE FOR MEASURING THE CONCENTRATION OF AN ANALYTE IN AN EYE LIQUID
WO2004099824A2 (en) * 2003-05-02 2004-11-18 Oculir, Inc. Methods and device for non-invasive analyte measurement
ES2350933T3 (en) * 2003-08-07 2011-01-28 Eyesense Ag OPHTHALM SENSOR
DK1758500T3 (en) * 2004-06-14 2010-01-18 Eyesense Ag Combined apparatus for measuring blood glucose level from an eye fluid
CN101076728A (en) 2004-12-13 2007-11-21 拜尔保健有限公司 A method of differentiating between blood and control solutions containing a common analyte
DE502006002076D1 (en) 2006-07-24 2008-12-24 Eyesense Ag Device for measuring an analyte in an eye fluid
DE102007003341B4 (en) 2007-01-17 2018-01-04 Eyesense Ag Eyepiece sensor and measuring system for detecting an analyte in an eye fluid
DE102007024642A1 (en) 2007-05-24 2008-11-27 Eyesense Ag Hydrogel implant for sensor of metabolites on the eye
US20090014340A1 (en) * 2007-06-15 2009-01-15 Williams John R Devices, systems, and methods for measuring glucose
GB2451441B (en) 2007-07-30 2012-07-11 Lein Applied Diagnostics Ltd Optical alignment apparatus and method thereof
US9042967B2 (en) 2008-05-20 2015-05-26 University Health Network Device and method for wound imaging and monitoring
US8181531B2 (en) * 2008-06-27 2012-05-22 Edwin Carlen Accessible stress-based electrostatic monitoring of chemical reactions and binding
US9011670B2 (en) * 2008-08-14 2015-04-21 The Charles Stark Draper Laboratory, Inc. Three-dimensional metal ion sensor arrays on printed circuit boards
DE502008003439D1 (en) 2008-10-02 2011-06-16 Eyesense Ag Implantation device for metabolite sensors
EP2174586B1 (en) 2008-10-02 2014-12-10 EyeSense AG Implantable sensor element
GB2467340B (en) 2009-01-30 2013-11-13 Lein Applied Diagnostics Ltd Signal sample trigger apparatus, data acquisition system and method of sampling an analogue signal
US9517023B2 (en) 2009-06-01 2016-12-13 Profusa, Inc. Method and system for directing a localized biological response to an implant
US10010272B2 (en) 2010-05-27 2018-07-03 Profusa, Inc. Tissue-integrating electronic apparatus
CA2813041C (en) 2010-10-06 2018-08-21 Natalie Ann Wisniewski Tissue-integrating sensors
EP2652500B1 (en) 2010-12-17 2016-05-11 EyeSense AG Competitive biosensor having elevated sensitivity
CN103370623B (en) 2010-12-17 2016-05-04 视觉股份公司 The purposes of hydrogel in the biology sensor of sensitivity with raising
US9724022B2 (en) 2011-04-29 2017-08-08 Taiwan Biophotonic Corporation Apparatus for non-invasive glucose monitoring
CN105266824A (en) 2011-04-29 2016-01-27 台医光电科技股份有限公司 Method for non-invasive blood glucose monitoring and method for analysing biological molecule
US9662004B2 (en) 2011-04-29 2017-05-30 Taiwan Biophotonic Corporation Apparatus for non-invasive glucose monitoring
US9101297B2 (en) 2012-12-11 2015-08-11 Elwha Llc Time-based unobtrusive active eye interrogation
EP2931113A4 (en) * 2012-12-11 2016-09-14 Allen L Brown Jr Unobtrusive active eye interrogation
US9039179B2 (en) 2012-12-11 2015-05-26 Elwha Llc Unobtrusive active eye interrogation
US9039180B2 (en) 2012-12-11 2015-05-26 Elwah LLC Self-aligning unobtrusive active eye interrogation
CA2904031A1 (en) 2013-03-14 2014-10-02 Profusa, Inc. Method and device for correcting optical signals
US20140350370A1 (en) * 2013-04-08 2014-11-27 The Texas A&M University System Glucose sensing assay
EP3777656A1 (en) 2013-06-06 2021-02-17 Profusa, Inc. Apparatus for detecting optical signals from implanted sensors
US9452260B2 (en) * 2013-11-22 2016-09-27 Verily Life Sciences Llc Closed loop control system based on a non-invasive continuous sensor
CN115989999A (en) 2014-07-24 2023-04-21 大学健康网络 Collection and analysis of data for diagnostic purposes
US10987033B2 (en) 2015-11-11 2021-04-27 Microoptx Inc. Aqueous humor monitoring devices and methods
WO2018119400A1 (en) 2016-12-22 2018-06-28 Profusa, Inc. System and single-channel luminescent sensor for and method of determining analyte value
WO2018187693A1 (en) 2017-04-06 2018-10-11 TearDX LLC Ocular devices and methods for the employment thereof
WO2019068026A1 (en) 2017-09-29 2019-04-04 Glaukos Corporation Intraocular physiological sensor
US11291391B2 (en) 2017-12-11 2022-04-05 Microoptx Inc. Implantable ocular glucose sensor devices and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569354A (en) * 1982-03-22 1986-02-11 Boston University Method and apparatus for measuring natural retinal fluorescence
US5341805A (en) * 1993-04-06 1994-08-30 Cedars-Sinai Medical Center Glucose fluorescence monitor and method
US5433197A (en) * 1992-09-04 1995-07-18 Stark; Edward W. Non-invasive glucose measurement method and apparatus
US6040194A (en) * 1989-12-14 2000-03-21 Sensor Technologies, Inc. Methods and device for detecting and quantifying substances in body fluids
US6088606A (en) * 1999-03-22 2000-07-11 Spectrx, Inc. Method and apparatus for determining a duration of a medical condition
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3653841A (en) * 1969-12-19 1972-04-04 Hoffmann La Roche Methods and compositions for determining glucose in blood
US3925178A (en) 1970-04-17 1975-12-09 Hymie D Gesser Contact lenses
US3731681A (en) 1970-05-18 1973-05-08 Univ Minnesota Implantable indusion pump
US4014321A (en) * 1974-11-25 1977-03-29 March Wayne F Non-invasive glucose sensor system
US4099859A (en) 1974-12-02 1978-07-11 High Voltage Engineering Corporation Contact lens having a smooth surface layer of a hydrophilic polymer
US4143949A (en) 1976-10-28 1979-03-13 Bausch & Lomb Incorporated Process for putting a hydrophilic coating on a hydrophobic contact lens
FR2385763A1 (en) 1977-03-31 1978-10-27 Essilor Int PROCESS FOR PREPARING COPOLYMERS SILICONE GRAFTS
US4168112A (en) 1978-01-05 1979-09-18 Polymer Technology Corporation Contact lens with a hydrophilic, polyelectrolyte complex coating and method for forming same
US4217038A (en) 1978-06-05 1980-08-12 Bausch & Lomb Incorporated Glass coated polysiloxane contact lens
US4573994A (en) 1979-04-27 1986-03-04 The Johns Hopkins University Refillable medication infusion apparatus
CH641063A5 (en) 1979-12-06 1984-02-15 Balzers Hochvakuum METHOD FOR COATING A SURFACE PART OF AN ELASTIC BODY WITH A CONTINUOUS LAYER.
FR2483310A1 (en) 1980-05-29 1981-12-04 Fibar Ste Civile Immob TREATMENT PROCESS FOR MAKING HYDROPHILIC CONTACT LENSES HYDROPHILIC
US4332922A (en) 1980-07-18 1982-06-01 Titmus Eurocon Process for rendering silicone rubber contact lenses hydrophilic
US4311573A (en) 1980-10-08 1982-01-19 American Hospital Supply Corporation Process for graft copolymerization of a pre-formed substrate
US4589964A (en) 1980-10-08 1986-05-20 American Hospital Supply Corporation Process for graft copolymerization of a pre-formed substrate
DE3313047A1 (en) * 1983-04-12 1984-10-18 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen ARRANGEMENT FOR MEASURING DIFFUSING PARTICLES
US5041133A (en) 1984-04-11 1991-08-20 Pharmacia Ab Intraocular implant
DK160633C (en) 1985-05-15 1991-09-02 Henning Munk Ejlersen HOSE PUMP, ISSUE FOR EVENING AS INSULIN PUMP
US4799931A (en) 1986-05-14 1989-01-24 Lindstrom Richard L Intracorneal lens
US5040194A (en) 1986-07-15 1991-08-13 Hayes Microcomputer Products, Inc. Method and apparatus for providing for automatic gain control of incoming signals in a modem
EP0308077A3 (en) 1987-09-14 1990-05-30 Nestle S.A. Synthetic intracorneal lens
FR2631228B1 (en) 1988-05-11 1990-08-10 Domilens Laboratoires INTRA-EYE IMPLANT OF PREVIOUS CHAMBER
JPH01300958A (en) 1988-05-31 1989-12-05 Canon Inc Intraocular lens having surface functional film
US4983702A (en) 1988-09-28 1991-01-08 Ciba-Geigy Corporation Crosslinked siloxane-urethane polymer contact lens
US5115133A (en) * 1990-04-19 1992-05-19 Inomet, Inc. Testing of body fluid constituents through measuring light reflected from tympanic membrane
US5127901A (en) 1990-05-18 1992-07-07 Odrich Ronald B Implant with subconjunctival arch
CA2053449A1 (en) 1990-10-16 1992-04-17 Henry K. Hui Optical fiber ph microsensor and method of manufacture
GB9114603D0 (en) 1991-07-05 1991-08-21 Johnson David P Improvements relating to patella prostheses
US5203328A (en) * 1991-07-17 1993-04-20 Georgia Tech Research Corporation Apparatus and methods for quantitatively measuring molecular changes in the ocular lens
US5400114A (en) 1991-09-05 1995-03-21 Hitachi, Ltd. Rear-projection screen and a rear projection image display employing the rear-projection screen
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6090141A (en) 1993-03-05 2000-07-18 Lindstrom; Richard L. Small intracorneal lens
US5894002A (en) 1993-12-13 1999-04-13 Ciba Vision Corporation Process and apparatus for the manufacture of a contact lens
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
TW258686B (en) 1994-03-07 1995-10-01 Ciba Geigy
JPH0838460A (en) * 1994-08-03 1996-02-13 Mitsubishi Electric Corp Brain activity measuring device
US5760100B1 (en) 1994-09-06 2000-11-14 Ciba Vision Corp Extended wear ophthalmic lens
US5762836A (en) 1994-10-14 1998-06-09 W.K. & Associes Method for making an intraocular implant with a soft lens
US5776361A (en) * 1995-02-15 1998-07-07 Chevron Chemical Company Multi-component oxygen scavenging composition
IL113723A (en) 1995-05-14 2002-11-10 Optonol Ltd Intraocular implant
EP0781526B1 (en) * 1995-12-13 2004-09-15 Akitoshi Yoshida Measuring apparatus for intraocular substance employing light from eyeball
JP3599878B2 (en) * 1996-03-01 2004-12-08 テルモ株式会社 Blood glucose meter
FR2746000B1 (en) 1996-03-14 1998-06-12 FLEXIBLE INTRAOCULAR IMPLANT AND SET OF SUCH IMPLANTS
US5807944A (en) 1996-06-27 1998-09-15 Ciba Vision Corporation Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom
US5894961A (en) * 1997-01-24 1999-04-20 Kaufman Products Inc. Dispenser with resilient reservoir structure
US5957890A (en) 1997-06-09 1999-09-28 Minimed Inc. Constant flow medication infusion pump
US5984961A (en) 1997-12-02 1999-11-16 Macoul; Kenneth L. Intracorneal prism and method of improving vision in a human eye having macula disease
DE69908084T2 (en) 1998-01-09 2003-11-27 Novartis Ag COATING POLYMERS
US6086606A (en) * 1998-05-06 2000-07-11 Knodel; Bryan D. Manually-operable surgical tool suitable for laparoscopic operations, readily adaptable for different functions by quick change of tissue-contacting operational elements
US6064897A (en) * 1998-06-01 2000-05-16 Abbott Laboratories Sensor utilizing Raman spectroscopy for non-invasive monitoring of analytes in biological fluid and method of use
AU4986899A (en) * 1998-07-13 2000-02-01 Children's Hospital Of Los Angeles Non-invasive glucose monitor
KR20010102951A (en) * 1998-12-02 2001-11-17 추후제출 In vivo biosensor apparatus and method of use
CA2381520C (en) * 1999-08-26 2009-05-26 Novartis Ag Ocular analyte sensor
US6442409B1 (en) * 2000-03-22 2002-08-27 Gholam A. Peyman Diagnostic system and method using radiant energy and implants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569354A (en) * 1982-03-22 1986-02-11 Boston University Method and apparatus for measuring natural retinal fluorescence
US6040194A (en) * 1989-12-14 2000-03-21 Sensor Technologies, Inc. Methods and device for detecting and quantifying substances in body fluids
US5433197A (en) * 1992-09-04 1995-07-18 Stark; Edward W. Non-invasive glucose measurement method and apparatus
US5341805A (en) * 1993-04-06 1994-08-30 Cedars-Sinai Medical Center Glucose fluorescence monitor and method
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6088606A (en) * 1999-03-22 2000-07-11 Spectrx, Inc. Method and apparatus for determining a duration of a medical condition

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147820A1 (en) * 2001-09-13 2004-07-29 Fovioptics, Inc. Non-invasive measurement of blood analytes using photodynamics
US8137985B2 (en) 2001-12-24 2012-03-20 Kimberly-Clark Worldwide, Inc. Polyelectrolytic internal calibration system of a flow-through assay
US7651841B2 (en) * 2001-12-24 2010-01-26 Kimberly-Clark Worldwide, Inc. Polyelectrolytic internal calibration system of a flow-through assay
US20040087843A1 (en) * 2002-08-26 2004-05-06 Rice Mark J. Non-invasive psychophysical measurement of glucose using photodynamics
US20050010091A1 (en) * 2003-06-10 2005-01-13 Woods Joe W. Non-invasive measurement of blood glucose using retinal imaging
US7769419B2 (en) 2003-10-24 2010-08-03 Lein Applied Diagnostics Limited Ocular property measuring apparatus and method therefor
US7781172B2 (en) 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US7943395B2 (en) 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US20070123761A1 (en) * 2003-12-12 2007-05-31 Daly Daniel J Extended focal region measuring apparatus and method
US8078245B2 (en) 2003-12-12 2011-12-13 Lein Applied Diagnostics Limited Extended focal region measuring apparatus and method
US7909983B2 (en) * 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
US20070256943A1 (en) * 2006-05-04 2007-11-08 Popovich Natasha D System and methods for automatically recognizing a control solution
US20100210925A1 (en) * 2007-07-30 2010-08-19 Richard Holley Optical Apparatus for Measuring a Physiological Property of a Body Part and Method Therefore
US8696128B2 (en) 2007-07-30 2014-04-15 Lein Applied Diagnostics Optical measurement apparatus and method therefor
US9026188B2 (en) 2008-02-11 2015-05-05 Lein Applied Diagnostics Measurement apparatus and method therefor
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor
US10849558B2 (en) 2013-03-13 2020-12-01 Glaukos Corporation Intraocular physiological sensor
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
EP2979662A1 (en) 2014-08-01 2016-02-03 Akkolens International B.V. Intraocular lens with electricity generator and additional functional systems
US9459202B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for collision computing for detection and noninvasive measurement of blood glucose and other substances and events
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9453794B2 (en) 2014-09-29 2016-09-27 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
US9459203B2 (en) 2014-09-29 2016-10-04 Zyomed, Corp. Systems and methods for generating and using projector curve sets for universal calibration for noninvasive blood glucose and other measurements
US9610018B2 (en) 2014-09-29 2017-04-04 Zyomed Corp. Systems and methods for measurement of heart rate and other heart-related characteristics from photoplethysmographic (PPG) signals using collision computing
US9448165B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for control of illumination or radiation collection for blood glucose and other analyte detection and measurement using collision computing
US9448164B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing

Also Published As

Publication number Publication date
NO20034777L (en) 2003-10-24
JP4152193B2 (en) 2008-09-17
US20060178572A1 (en) 2006-08-10
NO20034777D0 (en) 2003-10-24
EP1385423A1 (en) 2004-02-04
WO2002087429A1 (en) 2002-11-07
US20100185066A1 (en) 2010-07-22
DK1385423T3 (en) 2008-03-25
CA2441787A1 (en) 2002-11-07
CA2441787C (en) 2011-08-09
EP1385423B1 (en) 2007-11-21
US7653424B2 (en) 2010-01-26
DE60223668D1 (en) 2008-01-03
JP2004528103A (en) 2004-09-16
ES2295344T3 (en) 2008-04-16
DE60223668T2 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
US7653424B2 (en) Apparatus for measuring blood glucose concentrations
US6850786B2 (en) Ocular analyte sensor
US6980842B2 (en) Ocular analyte sensor
CA2570035C (en) Combined apparatus for measuring the blood glucose level from an ocular fluid
US7406345B2 (en) Apparatus for measuring an analyte concentration from an ocular fluid
WO2002003855A1 (en) Optical device for measurement of analytes in tears
ZA200201427B (en) Ocular analyte sensor.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MARCH, WAYNE FRONT;REEL/FRAME:019623/0826

Effective date: 20031112

AS Assignment

Owner name: EYESENSE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS AG;REEL/FRAME:019666/0300

Effective date: 20061106